Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed infiltrating carcinoma of the breast meeting any of the following criteria: * T1-3, any N disease * Proven ductal carcinoma in situ * Unresected disease * Planned mastectomy as definitive surgical procedure * Known or suspected metastatic disease allowed provided mastectomy is planned * Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy) * No inflammatory breast cancer or other T4 features * Successful baseline ductogram * Baseline nipple aspiration procedure must identify a duct productive of nipple aspirate fluid * No severe nipple retraction * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Female patients * Menopausal status not specified * ECOG performance status 0-2 * Absolute neutrophil count ≥1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Creatinine ≤ 2 times upper limit of normal (ULN) * Bilirubin ≤ 2 times ULN * AST and ALT ≤ 2.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No significant history of severe allergy to iodinated contrast material or debilitating anxiety that may not allow for a ductogram PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy allowed provided it was completed 7-14 days prior to study treatment * No prior radiation therapy, excisional biopsy, breast reduction, areolar surgery, or breast implant (present or past history of implant that was removed) * No other prior procedure that may have altered the breast ductal system in the ipsilateral breast * No other concurrent chemotherapy, radiotherapy, endocrine therapy, or biologic agents for breast cancer * No other concurrent investigational drugs * Concurrent bisphosphonates allowed